Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients

BACKGROUND: Hypoxia is a driver of treatment resistance in glioblastoma. Antiangiogenic agents may transiently normalize blood vessels and decrease hypoxia before excessive pruning of vessels increases hypoxia. The time window of normalization is dose and time dependent. We sought to determine how V...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neurooncol Adv
Autori principali: Gerstner, Elizabeth R, Emblem, Kyrre E, Yen, Yi-Fen, Dietrich, Jorg, Jordan, Justin T, Catana, Ciprian, Wenchin, Kevin Lou, Hooker, Jacob M, Duda, Dan G, Rosen, Bruce R, Kalpathy-Cramer, Jayashree, Jain, Rakesh K, Batchelor, Tracy T
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7764510/
https://ncbi.nlm.nih.gov/pubmed/33392506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa157
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi